Updated data from the EMBER trial of imlunestrant, a new oral selective estrogen receptor degrader showing sustained inhibition of estrogen receptor (ER)-dependent gene transcription and cell proliferation, have been released. Read More ›

Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported. Read More ›

Pembrolizumab plus chemotherapy increased event-free survival compared with chemotherapy alone, highlighting the relevance of neoadjuvant pembrolizumab therapy for improving survival in patients with early triple-negative breast cancer. Read More ›

Patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who had previously advanced on any cyclin-dependent kinase (CDK)4/6 inhibitor plus any endocrine therapy (ET) showed a substantial progression-free survival (PFS) advantage in the ribociclib-treated cohort. Read More ›

The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor. Read More ›

DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy. Read More ›

Several novel breast cancer therapies have come onto the market in recent years, significantly changing the breast cancer landscape, specifically in the metastatic setting. The Pathways Heart Study has looked at cardiovascular outcomes and risk variables from breast cancer treatments. A number of breast cancer risk factors as well as the benefits of physical exercise and aspirin use among breast cancer survivors are discussed in this review. Read More ›

Tucatinib added to trastuzumab and capecitabine resulted in a substantial and permanent improvement of progression-free survival and overall survival for all patients with HER2-positive metastatic breast cancer with brain metastases, as confirmed by results from the HER2CLIMB study. Read More ›

Tucatinib-containing therapy resulted in a tumor volume reduction of >80%. Tucatinib was found to be highly effective when combined with paclitaxel plus trastuzumab plus pertuzumab. Read More ›